Results 41 to 50 of about 8,384 (181)

Effects of Incretin‐Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat‐Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Maintaining fat‐free mass (FFM) during weight loss is important to maintain a healthy body composition. This review examined changes in FFM during weight loss induced by diet and exercise interventions, incretin‐based therapies, and bariatric surgery, and assessed whether the relative loss of FFM differs by weight‐loss modality ...
Laura Busk‐Cirera, Ida Ørum Carlsen, Lærke Bruun Madsen, Rasmus Michael Sandsdal, Emma Jensen, Simon Birk Kjær Jensen, Signe Sørensen Torekov   +6 more
wiley   +1 more source

Molecular Mechanisms of Protein–Lipid Interactions and Protein Folding of Heterogeneous Amylin and Tau Oligomers on Lipid Nanodomains That Link to Alzheimer’s

Macromol, 2023
The disruption of cell membranes by tau and amylin oligomers is linked to amyloid diseases such as Alzheimer’s and diabetes, respectively. The recent studies suggest that misfolded tau and amylin can form neurotoxic hetero-oligomers that are structurally
Natalia Santos, Luthary Segura, Amber Lewis, Thuong Pham, Kwan H. Cheng   +4 more
doaj   +1 more source

Prevalence of Obesity and Related Conditions and GLP‐1 Use in Medicare Fee‐for‐Service Beneficiaries

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study estimated the number and percentage of Medicare fee‐for‐service (FFS) beneficiaries who use GLP‐1 RAs, are currently eligible or could become eligible if ongoing‐trial indications receive approval and coverage. Materials and Methods This retrospective cohort study used Medicare enrolment and claims data, representing 100% of ...
Sonia Kim, Andrea Barthel, Marlene Smurzynski, Joanna MacEwan   +3 more
wiley   +1 more source

Relation between serum amylin level and epilepsy

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2020
Background Epilepsy is a neurological disorder characterized by convulsions. Identification of biological pathways underlying epilepsy and novel genes may shed light on the pathogenesis of epilepsy as well as new targets for treatment.
Necla Benlier, Gokhan Ozer, Nuri Orhan
doaj   +1 more source

Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin‐based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical ...
Matteo Monami, Benedetta Ragghianti, Edoardo Mannucci   +2 more
wiley   +1 more source

d -Retro Inverso Amylin and the Stability of Amylin Fibrils

Journal of Chemical Theory and Computation, 2020
Motivated by the role that amylin aggregates play in type-II diabetes, we compare the stability of regular amylin fibrils with the stability of fibrils where l-amino acid chains are replaced by d-retro inverso (DRI) amylin, that is, peptides where the sequence of amino acids is reversed, and at the same time, the l-amino acids are replaced by their ...
Preeti Pandey, Natalie Nguyen, Ulrich H.E. Hansmann   +2 more
openaire   +3 more sources

Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early‐Phase Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The management of the disease of obesity has been transformed by incretin‐based therapies; however, additional and alternative therapeutic strategies are needed to address its biological complexity. This narrative review examines the physiology of amylin and the emerging role of amylin‐based therapies in obesity management.
Abdulhameed Alhazmi, Carel W. le Roux
wiley   +1 more source

Serum amylin level in Behçet’s disease and relation to parameters of metabolic syndrome and disease activity

Egyptian Rheumatology and Rehabilitation, 2018
Background Insulin resistance is found in Behçet’s disease and associated with the development of metabolic syndrome. Our study explored whether amylin, which is involved in insulin resistance and development of metabolic syndrome, is observed in ...
Shimaa M Abdelwhab, Omima Z Shehata, Yousry A El Magd, Amal Kamal   +3 more
doaj   +1 more source

Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Zenagamtide is a novel, unimolecular glucagon‐like peptide‐1 and amylin receptor agonist in development for weight management and Type 2 diabetes. This study investigated the pharmacokinetic (PK) properties, safety and tolerability of zenagamtide in participants with various degrees of renal impairment versus participants with normal ...
Lykke Ida Kaas Oldenburg, Sine Pfeiffer Haugaard, Tobias Karlsson, Victoria Kegel‐Hübner, Mahera Parwez, Christoffer Wiingaard, Anne Flint   +6 more
wiley   +1 more source

Amylin and its Analogs: A Friend or Foe for the Treatment of Alzheimer’s Disease?

Frontiers in Aging Neuroscience, 2014
Amylin, a gut-brain axis hormone, and amyloid-beta peptides (Aβ), a major component of the Alzheimer’s disease (AD) brain, share several features, including similar β-sheet secondary structures, binding to the same receptor and being degraded by the same
Wei Qiao (Wendy) eQiu, Haihao eZhu
doaj   +1 more source